Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

BACKGROUND: The growth modulation index (GMI) is the ratio of time to progression with the nth line (TTP(n)) of therapy to the TTP(n)(−1) with the n-1th line. GMI >1.33 is considered as a sign of activity in phase II trials. PATIENTS AND METHODS: This retrospective analysis evaluated the concorda...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Oncol
Autori principali: Penel, N., Demetri, G. D., Blay, J. Y., Cousin, S., Maki, R. G., Chawla, S. P., Judson, I., von Mehren, M., Schöffski, P., Verweij, J., Casali, P., Rodenhuis, S., Schütte, H. J., Cassar, A., Gomez, J., Nieto, A., Zintl, P., Pontes, M. J., Le Cesne, A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2013
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4271084/
https://ncbi.nlm.nih.gov/pubmed/23117071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds470
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi